Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Servier to pay $130m for Taiho's mCRC drug in Europe

This article was originally published in Scrip

Executive Summary

Servier is to pay Taiho Pharmaceutical $130m in an upfront payment and European approval milestone for commercialization rights to TAS-102 (an oral combination of trifluridine and tipiracil hydrochloride) in Europe and other countries. The product is under review by the US FDA and the EMA for use in the treatment of refractory metastatic colorectal cancer (mCRC). If approved, it will face a competitive market. Taiho has retained commercialization rights in the US, Canada, Mexico and Japan/Asia and the rights to manufacture and supply the product. In addition to $130m, Taiho could receive additional regulatory and sales milestones and royalties. The companies will also collaborate on the further global development of TAS-102, sharing effort and cost on an equal basis. The regulatory filings were supported by data from the Phase III RECOURSE trial. The product was approved in Japan in 2014. If approved, Taiho's product will face competition from many well-established products including 5-fluorouracil and oxaliplatin, as well as Bayer's Stivarga (regorafenib). Servier will be hoping the fractionally better OS data for TAS-102 compared with Stivarga will help to differentiate the product.

You may also be interested in...

VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others

Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts